Clene (CLNN) 10% holder-linked LLC reports multi-day share sales

Rhea-AI Filing Summary

Clene Inc.’s 10% owner Ugwumba Chidozie reported a series of indirect share sales through Symbiosis II, LLC. On January 26, 2026, Symbiosis II, LLC sold 6,418 shares of Clene common stock at $5.02 per share. On January 27, 2026, it sold 4,139 shares at $5.08 per share. On January 28, 2026, it sold 8,717 shares at $4.91 per share. Following the latest transaction, Symbiosis II, LLC beneficially owned 580,329 Clene common shares indirectly attributed to the reporting person.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Ugwumba Chidozie

(Last) (First) (Middle)

609 SW 8TH STREET

SUITE 510

(Street)

BENTONVILLE AR 72712

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Clene Inc. [ CLNN ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director	X	10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
01/26/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	01/26/2026		S		6,418	D	$5.02	593,185	I	By Symbiosis II, LLC
Common Stock	01/27/2026		S		4,139	D	$5.08	589,046	I	By Symbiosis II, LLC
Common Stock	01/28/2026		S		8,717	D	$4.91	580,329	I	By SymBiosis II, LLC

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

	/s/ Chidozie Ugwumba	01/28/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider activity did Clene Inc. (CLNN) disclose in this Form 4?

Clene Inc. disclosed that an entity associated with 10% owner Ugwumba Chidozie, Symbiosis II, LLC, sold several blocks of common stock over three days in January 2026, while retaining a substantial remaining indirect position.

Who is the reporting person in this Clene Inc. (CLNN) Form 4 filing?

The reporting person is Ugwumba Chidozie, identified as a 10% owner of Clene Inc. The reported transactions involve shares held indirectly through Symbiosis II, LLC, rather than directly in his own name.

What share sales were reported for Clene Inc. (CLNN) on January 26–28, 2026?

Symbiosis II, LLC reported selling 6,418 Clene shares at $5.02 on January 26, 4,139 shares at $5.08 on January 27, and 8,717 shares at $4.91 on January 28, all as indirect transactions for the reporting person.

How many Clene Inc. (CLNN) shares remain held after these Form 4 sales?

After the final reported sale on January 28, 2026, Symbiosis II, LLC beneficially owned 580,329 Clene common shares. These shares are reported as being indirectly owned by 10% holder Ugwumba Chidozie through the LLC structure.

Are the reported Clene Inc. (CLNN) shares held directly or indirectly by the insider?

All reported shares are held indirectly through Symbiosis II, LLC, as indicated by the ownership form "I" and the nature of ownership description "By Symbiosis II, LLC" for each transaction and the remaining beneficial holdings.

What transaction code is used in this Clene Inc. (CLNN) Form 4 and what does it indicate?

Each transaction is marked with code “S”, which indicates a sale of common stock. The Form 4 lists the number of shares sold, the sale price per share, and the updated indirect holdings after each transaction date.